Jørn Herrstedt

Jørn Herrstedt

    Member of:

    • Clinical Oncology


    Publication year:
    All
    1 - 5 out of 5Page size: 10
    1. 2024
    2. Published

      Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC)

      Daviu Cobián, C., Oreskov, J. O., Blaakaer, J., Jespersen, E., Jørgensen, T. L., Ryg, J., Herrstedt, Jørn, Høgdall, Claus Kim, Lund, Cecilia Margareta, Seibæk, L., Vinther, A., Ekmann-Gade, A. W. & Schnack, T. H., 2024, In: Journal of Geriatric Oncology. 15, 3, 12 p., 101713.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

      Herrstedt, J., Clark-Snow, R., Ruhlmann, C. H., Molassiotis, A., Olver, I., Rapoport, B. L., Aapro, M., Dennis, K., Hesketh, P. J., Navari, R. M., Schwartzberg, L., Affronti, M. L., Garcia-Del-Barrio, M. A., Chan, A., Celio, L., Chow, R., Fleury, M., Gralla, R. J., Giusti, R., Jahn, F. & 14 others, Iihara, H., Maranzano, E., Radhakrishnan, V., Saito, M., Sayegh, P., Bosnjak, S., Zhang, L., Lee, J., Ostwal, V., Smit, T., Zilic, A., Jordan, K., Scotté, F. & participants of the MASCC/ESMO Consensus Conference 2022, P. O. T. M. C. C. 2., 2024, In: ESMO Open. 9, 2, 18 p., 102195.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

      Meteran, H., Knudsen, A. &., Jørgensen, T. L., Nielsen, D. & Herrstedt, Jørn, 2024, In: Journal of Clinical Medicine. 13, 3, 12 p., 897.

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

      Rapoport, B. L., Herrstedt, Jørn, Snow, R. C., Radhakrishnan, V., Saito, M., Navari, R. M. & Smit, T., 2024, In: Supportive Care in Cancer. 32, 7 p., 36.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

      Scotté, F., Schwartzberg, L., lihara, H., Aapro, M., Gralla, R., Hesketh, P. J., Jordan, K., Chow, R. & Herrstedt, Jørn, 2024, In: Supportive Care in Cancer. 32, 9 p., 45.

      Research output: Contribution to journal › Journal article › Research › peer-review

    ID: 182566628